Experimental cancer combo trial halted early

NCT ID NCT06337630

Terminated Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested two experimental drugs, tuvusertib and PLX038, in 10 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find a safe dose and see if the combination could shrink tumors. However, the study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tuvusertib and PLX038
What this could lead to: If it works, this combination could point toward a new treatment option for advanced solid tumors that have stopped responding to standard chemotherapy.
What could go wrong: This was a very early, small phase 1 trial that was terminated before completion. It is unclear if the combination is safe or effective, and it may never reach patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Institut Curie

Paris, 75005, France
Institut Curie

Saint-Cloud, 92210, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.